Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Pradaxa®

First Posted Date: 2017-06-14

Last Posted Date: 2020-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1315

Registration Number: NCT03187197

Locations: 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳
Show Chwan Memorial Hospital, Changhua, Taiwan

and more 21 locations

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 456906
Drug: Placebo

First Posted Date: 2017-06-05

Last Posted Date: 2018-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT03175211

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Japanese Pradaxa PMS, Long Term

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Prazaxa® Capsules

First Posted Date: 2017-06-05

Last Posted Date: 2022-04-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5660

Registration Number: NCT03175198

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Phase 1

Terminated

Conditions: Neoplasms
Neoplasm Metastasis
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BI 891065
Drug: BI 754091

First Posted Date: 2017-05-25

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT03166631

Locations: 🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Phase 2

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: BI 1467335
Drug: Placebo

First Posted Date: 2017-05-25

Last Posted Date: 2020-06-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 114

Registration Number: NCT03166735

Locations: 🇨🇦
Toronto Liver Centre, Toronto, Ontario, Canada
🇳🇱
Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 40 locations

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Phase 1

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: BI 685509
Drug: Placebo

First Posted Date: 2017-05-24

Last Posted Date: 2020-01-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 75

Registration Number: NCT03165227

Locations: 🇺🇸
Indago Research and Health Center, Hialeah, Florida, United States
🇺🇸
Research by Design, LLC, Chicago, Illinois, United States
🇺🇸
Houston Clinical Research Associates, Houston, Texas, United States

and more 32 locations

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: BI 690517
Drug: Eplerenone
Drug: Placebo

First Posted Date: 2017-05-24

Last Posted Date: 2020-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT03165240

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
🇩🇰
Bispebjerg og Frederiksberg Hospital, København NV, Denmark
🇩🇰
Copenhagen University Hospital, Rigshospitalet, København Ø, Denmark

and more 37 locations

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiolto® Respimat®

First Posted Date: 2017-05-24

Last Posted Date: 2020-04-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1351

Registration Number: NCT03165045

Locations: 🇩🇪
Dr. Urban, Berlin, Germany
🇩🇪
Dr. Kassik, Bitterfeld-Wolfen, Germany
🇩🇪
Praxis B. Metzlaff, Büchen, Germany

and more 103 locations

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1467335
Drug: Placebo

First Posted Date: 2017-05-18

Last Posted Date: 2021-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT03159455

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib
Drug: pembrolizumab

First Posted Date: 2017-05-17

Last Posted Date: 2021-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03157089

Locations: 🇫🇷
HOP Côte de Nacre, Caen, France
🇫🇷
HOP Le Mans, Le Mans, France
🇺🇸
Baptist Health Medical Group, Lexington, Kentucky, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy